白细胞介素-8和血管内皮生长因子受体-2基因多态性调节渗出性年龄相关性黄斑变性患者玻璃体内注射雷珠单抗的长期功能反应。
IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.
作者信息
Lazzeri Stefano, Orlandi Paola, Piaggi Paolo, Sartini Maria Sole, Casini Giamberto, Guidi Gianluca, Figus Michele, Fioravanti Anna, Di Desidero Teresa, Ripandelli Guido, Parravano Mariacristina, Varano Monica, Nardi Marco, Bocci Guido
机构信息
Ophthalmology Unit, University of Pisa, Pisa, Italy.
Fondazione G. B. Bietti, IRCCS Rome, Italy.
出版信息
Pharmacogenomics. 2016;17(1):35-9. doi: 10.2217/pgs.15.153. Epub 2015 Dec 14.
AIM
To investigate possible associations between VEGFR-2 and IL-8 gene SNPs and 1-year response to intravitreal ranibizumab for exudative age-related macular degeneration.
MATERIALS & METHODS: Sixty-four eyes underwent a loading phase of three monthly intravitreal injections of ranibizumab 0.5 mg/0.05 ml followed by Pro Re Nata retreatment. VEGFR-2 rs2071559 (-604 A/G) and IL-8 rs4073 (-251 A/T) were analyzed.
RESULTS
Ranibizumab was significantly more effective as measured by visual acuity in patients harboring the IL-8 rs4073 TT genotype (p = 0.045), whereas patients carrying the VEGFR-2 rs2071559 CC genotype revealed better functional response as measured by mean retinal sensitivity (p = 0.034).
CONCLUSION
IL-8 rs4073 and VEGFR-2 rs2071559 genotypes may represent important molecular determinants to modulate final outcomes in neovascular age-related macular degeneration patients.
目的
研究血管内皮生长因子受体-2（VEGFR-2）和白细胞介素-8（IL-8）基因单核苷酸多态性（SNPs）与玻璃体内注射雷珠单抗治疗渗出性年龄相关性黄斑变性1年疗效之间的可能关联。
材料与方法
64只眼接受了每月1次、共3次的玻璃体内注射0.5mg/0.05ml雷珠单抗的负荷期治疗，随后根据需要进行再次治疗。分析VEGFR-2 rs2071559（-604 A/G）和IL-8 rs4073（-251 A/T）。
结果
携带IL-8 rs4073 TT基因型的患者，以视力衡量，雷珠单抗的疗效显著更好（p = 0.045）；而携带VEGFR-2 rs2071559 CC基因型的患者，以平均视网膜敏感度衡量，显示出更好的功能反应（p = 0.034）。
结论
IL-8 rs4073和VEGFR-2 rs2071559基因型可能是调节新生血管性年龄相关性黄斑变性患者最终治疗结果的重要分子决定因素。
Zotero 插件